Not Tagged
novartis
['novartis']
 that is very impressive data indeed but the remaining problem is we need bio markers to identify
patients with hr+ tumours who benefit from cdk inhibitors as fist line therapy. best would liquid bio markers 
I'm a @breastcancer researcher at @UManitoba. I will share exciting and cutting edge research discoveries here. All opinions/comments are my own.